Clinical Trial Update: Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update examining pomalidomide after CAR T-cell therapy for relapsed or refractory CD19+ B-cell leukemia or lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Pomalyst (pomalidomide)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Status: NOT_YET_RECRUITING